Compare Oracle Corporation (ORCL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Oracle Corporation trades at $127.98 (market cap $434.11B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Oracle Corporation is far larger — about 89× Travere Therapeutics Inc. Common Stock's market cap, and Oracle Corporation pays a 1.4% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 73 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ORCL | TVTX | |
|---|---|---|
Market Cap | $434.11B | $4.88B |
Volume | 25,917,551 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $313.00 | $67.52 |
52-Week Low | $114.99 | $26.79 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $557.92B | $5.01B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $143.22, up 4.24% today, but faces a bearish technical signal with the stock near support at $135. The company reported strong Q1 2026 earnings, beating EPS estimates with $2.11 versus $1.96 expected, and maintains robust profitability with a 26.36% net income margin. Revenue growth accelerated to $57.4 billion in 2025, up from $53.0 billion in 2024, driven by AI cloud demand.
Outlook remains positive given analyst consensus price target of $236.52, implying significant upside, but risks include high debt levels and sensitivity to Fed policy. The stock's current valuation at a P/E of 22.45 appears reasonable relative to earnings growth, though investor sentiment is cautious amid recent layoffs and market volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
